Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon Expands its COVID-19 Therapeutic Program to include Artemisinin
In vitro data generated by the company and its collaborators supports the ability of artemisinin, an anti-malarial drug, to inhibit SARS-CoV-2 which can lead to COVID-19 Artemisinin complements OT-101 which continues to demonstrate potent activity against SARS-CoV-2 and expands the company’s
View HTML
Toggle Summary Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19
OT-101 - a TGF- β 2 antisense - has demonstrated potent antiviral activity against COVID-19   OT-101 is part of the Company’s proprietary platform for rapid antiviral response to COVID-19 and future viral epidemics AGOURA HILLS, Calif. , April 06, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
View HTML
Toggle Summary MATEON THERAPEUTICS TEAM PUBLISHES A NEW PEER-REVIEWED ONCOLOGY ARTICLE ON THE POSITIVE CLINICAL STUDY RESULTS FOR OT-101 AGAINST RECALCITRANT RESISTANT ANAPLASTIC ASTROCYTOMA – A RARE FORM OF MALIGNANT BRAIN TUMOR
AGOURA HILLS, Calif. , April 02, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD PhD, Sanjive Qazi PhD, and Vuong Trieu , PhD in the oncology journal Cancer Reports and Reviews.
View HTML
Toggle Summary Mateon Report Positive Results for Multiple COVID-19 Drug Candidates
OT-101 and two additional candidates demonstrated viral inhibition activity against coronavirus AGOURA HILLS, Calif. , March 25, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to the development of OT-101, a TGF-Beta antisense drug candidate, today provided an
View HTML
Toggle Summary Mateon Partners With Meridian IT To Fast Track Drug Manufacturing Using Artificial Intelligence For Coronaviruses, Including COVID-19
AGOURA HILLS, Calif. and DEERFIELD, Ill. , March 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) announced today their expanded focus on artificial intelligence (AI) enabled EdgePoint projects by expanding their partnership with Meridian IT, a leading technology
View HTML
Toggle Summary Mateon to Develop its OT-101, a Phase 3 Clinical Drug Candidate, Initially Against COVID-19
OT-101- a TGF- β 2 inhibitor - has demonstrated potent antiviral activity against coronavirus   OT-101 - an RNA therapeutic - is part of the Company’s proprietary platform for rapid antiviral response AGOURA HILLS, Calif. , March 18, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
View HTML
Toggle Summary Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19
Company has formed a new Division, led by Dr. Cyril Empig , to develop a multi-modal approach to treating the COVID-19 and future emergent zoonotic outbreaks Rapid response platform based on the Company’s proprietary small molecule, antisense, antibody and artificial intelligence (AI) technologies
View HTML
Toggle Summary Mateon Therapeutics Team Publishes a New Peer-Reviewed Oncology Article on the Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients With Relapsed Acute Myeloid Leukemia
AGOURA HILLS, Calif. , Dec. 27, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD. PhD, the Chief Medical Officer for Mateon, Vuong Trieu , PhD, the Chief Executive Officer and President
View HTML
Toggle Summary Mateon Therapeutics Announces Positive Clinical Study Results for Its Lead Anti-Leukemia Drug Combretastatin A1 Plus Cytarabine in Adult Patients with Relapsed Acute Myeloid Leukemia
AGOURA HILLS, Calif. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN), dedicated to the development of innovative treatments for cancer, today announced that the multi-institutional OXI1222 study in people with previously treated relapsed acute myeloid leukemia (AML) met
View HTML
Toggle Summary EdgePoint announces collaboration with iBio CDMO to implement AI/Blockchain driven TrustPoint Vision Technology in its Texas cGMP facility
TrustPoint has the potential to improve documentation processes by automating data documentation and verification leading to improved data integrity and reduced operating expenses Collaboration represents important step for commercialization of proprietary AI/blockchain vision technology by Mateon
View HTML